Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026)
Lyell Immunopharma recorded quarterly FCF Margin of 1929950.0% in Q1 2026, down 255.7% quarter-over-quarter from 542583.33% in Q4 2025, and down 114576429.0% year-over-year from N/an in Q1 2025.
Lyell Immunopharma's FCF Margin history runs 7 years deep, the most recent figure standing at 1929950.0% for Q1 2026.
- In Q1 2026, FCF Margin fell 114576429.0% year-over-year to 1929950.0%; the TTM figure through Mar 2026 stood at 433903.23% (down 16408015.0% YoY), while the FY2025 annual figure was 418900.0%, down 15244426.0% from the prior year.
- FCF Margin came in at 1929950.0% for Q1 2026 at Lyell Immunopharma, down from 542583.33% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 45.26% in Q4 2022 to a low of 1929950.0% in Q1 2026.
- A 5-year average of 478024.52% and a median of 295576.92% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 133026145 bps in 2022 and soared 117918000 bps in 2023, its largest moves.
- Lyell Immunopharma's FCF Margin stood at 45.26% in 2022, then plunged by 691031 bps to 312784.62% in 2023, then tumbled by 37 bps to 426963.64% in 2024, then retreated by 27 bps to 542583.33% in 2025, then tumbled by 256 bps to 1929950.0% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1929950.0%, 542583.33%, and 190926.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -1,929,950.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,929,950.00% |
| Dec 31, 2025 | -542,583.33% |
| Sep 30, 2025 | -190,926.67% |
| Jun 30, 2025 | -433,962.50% |
| Mar 31, 2025 | -784,185.71% |
| Dec 31, 2024 | -426,963.64% |
| Sep 30, 2024 | -103,238.24% |
| Jun 30, 2024 | -295,576.92% |
| Mar 31, 2024 | -1,401,533.33% |
| Dec 31, 2023 | -312,784.62% |
| Sep 30, 2023 | -150,620.00% |
| Jun 30, 2023 | -143,700.00% |
| Mar 31, 2023 | -71,703.08% |
| Dec 31, 2022 | -45.26% |
| Sep 30, 2022 | -1,329,800.00% |
| Jun 30, 2022 | -171.03% |
| Mar 31, 2022 | -8,672.51% |
| Dec 31, 2021 | -3,305.63% |
| Sep 30, 2021 | 461.45% |
| Jun 30, 2021 | -2,221.99% |
| Mar 31, 2021 | -2,158.98% |
| Dec 31, 2020 | -556.75% |
| Sep 30, 2020 | -3,905.51% |